Feedback PLC (GB:FDBK)
LSE:FDBK
Top Page
Feedback
(LSE:FDBK)
Select Model
Select Model
Rating:46Neutral
Price Target:
14.50 p
▲(56.76% Upside)
Action:ReiteratedDate:01/13/26
The score is held down primarily by deteriorating financial performance (sharp revenue decline, very large/worsening losses, and ongoing cash burn), partially offset by a debt-free balance sheet. Technicals add modest support due to an upward trend, but extremely overbought signals raise near-term risk. Valuation provides limited support given negative earnings and no dividend yield data.
Positive Factors
Debt-free balance sheet
Zero reported debt meaningfully reduces refinancing and interest burden risk for a cash-burning software provider. That conservative capital structure lengthens runway and preserves strategic optionality, giving management flexibility to pursue product investment or restructurings without leverage constraints.
Negative Factors
Sharp revenue decline
A ~26% top-line decline undermines the software scaling thesis: weaker adoption or renewals reduce ability to spread fixed costs, increase per-customer acquisition economics, and make it harder to leverage high gross margins into operating profitability. Sustained revenue shrinkage threatens long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt meaningfully reduces refinancing and interest burden risk for a cash-burning software provider. That conservative capital structure lengthens runway and preserves strategic optionality, giving management flexibility to pursue product investment or restructurings without leverage constraints.
Read all positive factors
Feedback (FDBK) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.70M
Dividend YieldN/A
Average Volume (3M)76.45K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth-25.05%
EPS Growth-5.74%
CountryUK
Employees27
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.04
Shares Outstanding43,814,777
10 Day Avg. Volume152,066
30 Day Avg. Volume76,453
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.67
Price to Sales (P/S)4.70
P/FCF Ratio-1.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.25
Revenue Forecast (FY)£810.00K
Feedback Business Overview & Revenue Model
Company Description
Feedback plc, a medical imaging technology company, provides software and systems to those working in the field of medical imaging. Its products include TexRAD, a patent-protected software tool, which extracts and quantifies texture features in ra...
How the Company Makes Money
Feedback (FDBK) makes money through a subscription-based revenue model, offering its software solutions to businesses on a monthly or annual basis. Key revenue streams include software licensing fees, customization services, and premium feature ad...
Feedback Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | May 2024 | May 2023 | May 2022 | May 2021 | May 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 849.62K | 885.62K | 1.18M | 1.02M | 588.58K | 287.42K |
| Gross Profit | 535.65K | 778.65K | 1.10M | 131.39K | -63.68K | 213.64K |
| EBITDA | -3.91M | -4.19M | -2.73M | -2.61M | -1.96M | -2.01M |
| Net Income | -7.18M | -7.32M | -3.30M | -2.92M | -2.12M | -1.62M |
Balance Sheet | ||||||
| Total Assets | 4.86M | 6.75M | 8.34M | 11.72M | 14.30M | 5.82M |
| Cash, Cash Equivalents and Short-Term Investments | 3.82M | 5.95M | 3.88M | 7.32M | 10.31M | 2.22M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 400.00K | 589.02K | 694.18K | 855.45K | 594.13K | 552.83K |
| Stockholders Equity | 4.46M | 6.16M | 7.64M | 10.87M | 13.71M | 5.27M |
Cash Flow | ||||||
| Free Cash Flow | -3.30M | -2.83M | -2.14M | -2.99M | -2.41M | -3.47M |
| Operating Cash Flow | -3.29M | -2.82M | -2.22M | -1.74M | -1.25M | -2.03M |
| Investing Cash Flow | -725.81K | -716.00K | -1.22M | -1.24M | -1.15M | -1.44M |
| Financing Cash Flow | 496.49K | 5.61M | 0.00 | -830.00 | 10.49M | 4.96M |
Feedback Technical Analysis
Neutral
9.25
Price Trends
12.38
Positive
10.74
Positive
11.72
Positive
Market Momentum
0.14
Positive
50.58
Neutral
29.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FDBK, the sentiment is Neutral. The current price of 9.25 is below the 20-day moving average (MA) of 13.34, below the 50-day MA of 12.38, and below the 200-day MA of 11.72, indicating a neutral trend. The MACD of 0.14 indicates Positive momentum. The RSI at 50.58 is Neutral, neither overbought nor oversold. The STOCH value of 29.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:FDBK.
Feedback Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £38.99M | -13.46 | 10.00% | ― | ― | ― | |
52 Neutral | £17.23M | -3.33 | -58.72% | ― | -30.77% | -6.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £7.30M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
47 Neutral | £15.65M | -1.51 | -153.92% | ― | 90.42% | 79.21% | |
46 Neutral | £5.70M | -0.50 | -135.17% | ― | -25.05% | -5.74% | |
40 Underperform | £8.80M | -0.25 | -316.67% | ― | 72.17% | 79.03% |
* Healthcare Sector Average
GB:FDBK
Feedback
13.00
-3.90
-23.08%
GB:COG
Cambridge Cognition Holdings
37.00
-2.00
-5.13%
GB:GDR
Genedrive
0.98
-0.54
-35.52%
GB:IXI
IXICO plc
7.88
-0.38
-4.55%
GB:OBD
Oxford BioDynamics
0.21
-0.28
-57.29%
GB:KOO
Kooth
107.50
-29.00
-21.25%
Feedback Corporate Events
Business Operations and StrategyFinancial Disclosures
Feedback plc invests for scale as Bleepa deepens NHS foothold
Positive
Feb 17, 2026
Feedback plc reported half-year results to 30 November 2025 showing stable revenue of £0.41m, with Bleepa contributing the majority, but a higher EBITDA loss of £1.61m as the company invested in support teams and cloud infrastructure. Ca...
Business Operations and StrategyFinancial Disclosures
Feedback plc Deepens NHS Integration as Losses Widen and National Bleepa Bid Advances
Neutral
Feb 17, 2026
Feedback plc reported stable first-half revenue of £0.41m to 30 November 2025, with its Bleepa platform contributing 89% of sales, while adjusted EBITDA losses widened to £1.61m due to increased hiring and cloud technology investment. Ca...
Business Operations and StrategyExecutive/Board Changes
Feedback appoints CFO Emma Oswick to board as it targets digital health growth
Positive
Feb 16, 2026
Feedback plc, the AIM-quoted clinical infrastructure specialist behind the Bleepa® collaboration platform, provides SaaS-based digital tools that connect healthcare systems, enable asynchronous clinical working and support the shift from anal...
Business Operations and StrategyFinancial Disclosures
Feedback plc sets date for interim results and retail investor presentation
Positive
Feb 2, 2026
Feedback plc, the clinical infrastructure and digital health collaboration specialist, will publish its interim results for the half year ended 30 November 2025 on 17 February 2026 and will host a retail investor presentation and QA the same after...
Business Operations and Strategy
Feedback Executives Increase Stakes with AIM Share Purchases
Positive
Dec 23, 2025
Feedback plc has disclosed that chief executive Tom Oakley and non-board chief financial officer Emma Oswick have both increased their holdings in the company through on-market share purchases on 23 December 2025. Oakley bought 60,904 ordinary sha...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.